Ziprasidone Mesylate Patent Expiration
Ziprasidone Mesylate is Used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis. It was first introduced by Viatris Specialty Llc
Ziprasidone Mesylate Patents
Given below is the list of patents protecting Ziprasidone Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Geodon | US6232304 | Inclusion complexes of aryl-heterocyclic salts |
Apr 01, 2017
(Expired) | Viatris |
| Geodon | US6399777 | Inclusion complexes of aryl-heterocyclic salts |
Apr 01, 2017
(Expired) | Viatris |
| Geodon | US6110918 | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar 26, 2017
(Expired) | Viatris |
Ziprasidone Mesylate's Family Patents
Explore Our Curated Drug Screens
Ziprasidone Mesylate Generic API Manufacturers
Several generic applications have been filed for Ziprasidone Mesylate. The first generic version for Ziprasidone Mesylate was by Gland Pharma Ltd and was approved on Dec 26, 2019. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Sep 15, 2022.
Given below is the list of companies who have filed for Ziprasidone Mesylate generic, along with the locations of their manufacturing plants worldwide.
1. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Ziprasidone Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE/VIAL | powder | Prescription | INTRAMUSCULAR | AP | Dec 26, 2019 |
2. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Ziprasidone Mesylate. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE/VIAL | powder | Prescription | INTRAMUSCULAR | AP | Sep 15, 2022 |
Manufacturing Plant Locations New
Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||
| United States |
| |||||||||||||||||||||